Add BrightSurf on Google Email

Study looks at Moderna COVID-19 vaccine effectiveness

A Kaiser Permanente study published in Nature Medicine found that three doses of the Moderna COVID-19 vaccine were highly effective against hospitalization caused by infection from either the omicron or delta variant. The research suggests that third doses may be needed sooner than previously thought to protect against omicron infectio...

SourceKaiser Permanente·JournalNature Medicine·DateFeb 22, 2022

UH sociologist finds disparities in initial COVID-19 vaccine distribution

A new study by University of Houston sociologist Kathryn Freeman Anderson reveals significant disparities in the initial COVID-19 vaccine rollout in five urban Texas counties. The research found that Black and Latino neighborhoods were less likely to receive vaccines due to existing healthcare resource shortages.

SourceUniversity of Houston·JournalJournal of Health and Social Behavior·TypeMeta-analysis·DateFeb 15, 2022

3 doses of Pfizer–BioNTech COVID vaccine better than 2

A Kaiser Permanente study found that a third dose of the Pfizer-BioNTech COVID-19 vaccine significantly improved protection against severe disease, hospitalization, and death. The study's results suggest that three doses of the vaccine provide greater benefit than two doses in preventing these outcomes.

SourceKaiser Permanente·JournalThe Lancet Regional Health - Americas·DateFeb 14, 2022

Most people with prior SARS-CoV-2 infection or vaccination have T cell immune responses against Omicron variant despite low antibody responses

A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.

SourceMassachusetts General Hospital·JournalCell·TypeObservational study·DateFeb 9, 2022

Omicron has mutations detected in previous variants, which explains vaccine effectiveness, scientists say

Researchers attribute vaccine effectiveness to mutations shared with previous variants, resulting in relatively small severe cases and deaths among vaccinated patients. The study analyzed over 200,000 genomes and found identical mutations that could serve as targets for future vaccines.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Medical Virology·DateFeb 8, 2022

First U.S. peer-reviewed study on omicron patient outcomes reveals rapid spread and significant differences in infection behavior

The first US peer-reviewed study on omicron patient outcomes found significant differences in infection behavior. Ominron patients are significantly younger, have increased vaccine breakthrough rates, and are less likely to be hospitalized compared to patients with alpha or delta variants.

SourceHouston Methodist·JournalAmerican Journal Of Pathology·TypeData/statistical analysis·DateFeb 3, 2022

Dose-finding trial paves way for new rotavirus vaccine to prevent a deadly diarrheal disease from birth

A phase 2 clinical trial found that the Australian-developed neonatal rotavirus vaccine RV3-BB was safe and produced a robust immune response in African babies. The reduced dose of the vaccine generated an equivalent immune response as the highest dose, offering opportunities to reduce vaccine manufacturing costs.

SourceMurdoch Childrens Research Institute·JournalThe Lancet Infectious Diseases·TypeRandomized controlled/clinical trial·DateFeb 3, 2022

Study finds fewer breakthrough COVID-19 infections, lower risk of hospitalization in those who received Moderna vaccine compared to Pfizer–BioNTech

A new study published in the Journal of the American Medical Association finds that those who received the Moderna COVID-19 mRNA vaccine have a lower risk of experiencing 'breakthrough' COVID-19 cases compared to recipients of the Pfizer-BioNTech mRNA vaccine. The study also found that Moderna recipients were less likely to be hospital...

SourceCase Western Reserve University·JournalJournal of the American Medical Association·DateJan 20, 2022

Vaccine used in much of the world no match for Omicron variant

A new study by Yale researchers found that the Sinovac vaccine, widely used in 48 countries, offers little protection against the Omicron variant. Booster shots are necessary to combat the dominant circulating virus, which has shown to produce no neutralizing antibodies among those who received two doses of the Sinovac vaccine.

SourceYale University·JournalNature Medicine·DateJan 20, 2022

Additional antibodies may protect against COVID

Researchers at Lund University discovered that non-neutralising antibodies can also protect against Covid-19 by facilitating phagocytosis. The findings suggest that broader protection from antibodies may be more effective in combating mutations of the virus.

SourceLund University·JournalFrontiers in Immunology·DateJan 17, 2022

Unique Irish study sheds new light on long-term SARS-CoV-2 vaccine responses in older nursing home residents

A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.

SourceTrinity College Dublin·JournalJournal of the American Medical Directors Association·TypeExperimental study·DateJan 11, 2022

Study compares COVID-19 vaccines’ ability to stimulate immune protection against the coronavirus

The study found that two doses of Moderna and Pfizer vaccines produced higher antibody concentrations than a single dose of Johnson & Johnson vaccine, with levels more than 10 times higher for recovered COVID-19 patients. The analysis also showed that the Moderna vaccine had the lowest risk for breakthrough infections.

SourceMassachusetts General Hospital·JournalThe Journal of Infectious Diseases·TypeObservational study·DateDec 20, 2021

mRNA vaccines highly effective at preventing death from COVID-19, less effective at preventing infection

Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateDec 20, 2021

The paradox of big data spoils vaccination surveys

Researchers from Harvard University and others have found that large-scale COVID-19 vaccination surveys were off by up to 17 percentage points due to systematic biases in the data. The 'Big Data Paradox' highlights how big data sets can minimize one type of error while magnifying another, leading to misleading results.

SourceHarvard University·JournalNature·DateDec 8, 2021

Year in pharma: COVID-19 and beyond

The COVID-19 pandemic drove significant advancements in pharmaceutical technology, with mRNA-based vaccines proving highly effective. Oral antiviral pills, such as Merck's molnupiravir and Pfizer's PF-0732133, showed promise in reducing hospitalization and death rates among unvaccinated individuals.

SourceAmerican Chemical Society·JournalChemical & Engineering News·DateDec 8, 2021

THE LANCET: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows

A UK trial shows six different COVID-19 boosters are safe and stimulate strong immune responses in people who have previously received a two-dose course of ChAdOx1-nCov19 or BNT162b2, according to the first randomised trial of boosters given after two doses. The study found varying levels of protection against COVID-19 infection and ho...

SourceThe Lancet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateDec 2, 2021

The Lancet Respiratory Medicine: Children with poorly controlled asthma at higher risk of COVID-19 hospitalization and should be prioritized for vaccination

A national analysis found that children with poorly controlled asthma are more likely to require hospitalisation than those with well-controlled asthma or without asthma. Vaccinating this group can reduce the risk of COVID-19 infection and associated illness.

SourceThe Lancet·JournalThe Lancet Respiratory Medicine·TypeObservational study·DateNov 30, 2021

Study on over a million people shows breakthrough COVID-19 infections occur more often and are more severe in immunocompromised

A large-scale study of over 1.2 million people found breakthrough COVID-19 infections are rare but more frequent and severe in those with weakened immune systems. The study supports the introduction of a third vaccine dose for immunocompromised individuals to increase protection.

SourceTaylor & Francis Group·JournalJournal of Medical Economics·TypeObservational study·DateNov 30, 2021

Do you need a COVID-19 booster shot?

A new study from the University of Georgia found that vaccination results in a more robust immune response than natural infection. Even with waning antibodies, vaccinated individuals still have protective immunity against severe disease and hospitalization.

SourceUniversity of Georgia·JournalFrontiers in Immunology·DateNov 16, 2021

Long-term immune response to Sputnik-V COVID vaccine

A study published in International Journal of Molecular Sciences found that the Sputnik-V COVID vaccine elicits both robust antibody and T-cell responses. The research suggests that long-term immunity is possible, supporting the effectiveness of the vaccine against local virus variants.

SourceKazan Federal University·JournalInternational Journal of Molecular Sciences·TypeObservational study·DateOct 26, 2021

Mandates likely work to increase vaccine uptake

Research from University of Pennsylvania team shows that vaccine mandates have positive effects on vaccination intentions, particularly for those who oppose forced behavior. Mandates strengthen vaccination intentions, regardless of racial or ethnic group, and for individuals with a disposition towards psychological reactance.

SourceUniversity of Pennsylvania·JournalScientific Reports·DateOct 21, 2021